Boehringer Ingelheim Contract Development and Manufacturing Services for Biopharmaceuticals
The Boehringer Ingelheim Group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
Contract development and manufacture of biopharmaceuticals
Today, Boehringer Ingelheim is one of the world’s leading companies for contract development and manufacture of biopharmaceuticals. All types of services from mammalian cell line or microbial strain development to final drug production can be delivered within a one-stop-shop concept. Boehringer Ingelheim delivers services for pre-clinical development up to global market supply with a strong commitment to its customers at its manufacturing facilities for mammalian cell culture and microbial fermentation.
Boehringer Ingelheim has brought 18 molecules to market and has many years of experience in multiple molecule classes such as monoclonal antibodies, recombinant proteins, interferons, enzymes, fusion molecules and plasmid DNA. Furthermore, high-titer platform technologies for new antibody mimetic formats such as scaffold proteins and antibody fragments are available for the manufacture of customer products.
Contract manufacturing of mammalian cell culture products and biopharmaceuticals
Boehringer Ingelheim offers the entire production technology chain at its biopharmaceutical manufacturing facilities in Vienna (Austria), Fremont (US) and Biberach (Germany). It has the world’s largest capacities for contract development and manufacturing of mammalian cell culture products and is one of the leading manufacturers of biopharmaceuticals.
Boehringer Ingelheim’s experience: process development (including proprietary high-expression systems in CHO, E.coli and yeasts) and manufacturing of biopharmaceuticals such as therapeutic proteins, monoclonal antibodies, antibody fragments, protein scaffolds, and plasmid DNA for clinical trials and global market supply.
Boehringer Ingelheim’s services in biopharmaceuticals manufacturing include:
Mammalian cell culture
Features of Boehringer Ingelheim’s mammalian cell culture services:
- Clinical material capacities: 80l to 2,000l
- Production capacities: 6 x 2,000l to 2 x 12,000l and 12 x 15,000l
- Fed-batch operations
Microorganism fermentation
Boehringer Ingelheim’s microorganism fermentation services include:
- Clinical material capacities: 30l to 6,000l
- Production capacities: 1 x 300l to 2 x 6,000l
- Batch or fed-batch fermentation
Downstream processing services
Boehringer Ingelheim’s biopharmaceuticals manufacturing services include downstream processing services:
- Multi-product purification suites
- Explosion-proof unit and preparative HPLC
- Viral inactivation procedures
Pharmaceutical manufacturing services
Boehringer Ingelheim’s expertise extends to pharmaceutical manufacturing:
- Up to 150,000 vials per batch aseptic filling
- Up to 100,000 syringes per batch aseptic filling
- Up to 150,000 cartridges per batch aseptic filling
Opportunities for Boehringer Ingelheim’s partners
Boehringer Ingelheim’s wide-ranging capabilities and expertise offer many advantages for its partners, including:
- One-stop-shop from DNA to final dosage form
- Project start without initial investment
- Supply of biopharmaceuticals up to large quantities
- Worldwide-licensed multi-product facilities on safety level 1
Boehringer Ingelheim Images
Products and Services
Video
White Papers
Related Projects
Boehringer Ingelheim’s Biopharmaceutical Production Facility in Vienna, Austria
Boehringer Ingelheim’s New Tablet Production Facility, Ingelheim
Boehringer Ingelheim’s Integrated Asian Veterinary R&D Centre, Shanghai
Boehringer Ingelheim Biologicals Development Centre (BDC), Biberach, Germany
Lonza Houston’s Biotech Facility, Pearland, Texas
Samsung BioLogics’ Third Manufacturing Facility, Songdo
Takeda Pharmaceutical’s High-Containment Production Facility, Grange Castle, Dublin
Boehringer Ingelheim Research Institute of Molecular Pathology (IMP)
Boehringer Ingelheim’s US Headquarters
Press Release
Boehringer Ingelheim has received the '2011 European Bio Pharmaceutical Contract Manufacturing Competitive Strategy Leadership Award' from Frost & Sullivan. The analysts recognised Boehringer Ingelheim Biopharmaceuticals as a global contract manufacturer that delivers excellence an
Read moreBoehringer Ingelheim and ProBioGen have announced that they have signed a non-exclusive licensing agreement regarding ProBioGen's GlymaxX® technology. Boehringer Ingelheim's Contract Manufacturing Business will apply the technology to enhance ADCC (antibody-dependent cell-mediated cytotoxici
Read moreTo round off its full-service capabilities for clients, Boehringer Ingelheim is expanding its capacities and capabilities in fill and finish for biopharmaceuticals at its state-of-the-art facility in Biberach, Germany, with a new filling line. The new line is available as of today for contract f
Read moreBoehringer Ingelheim has announced the US-registration for manufacturing of Bayer HealthCare's Betaferon® against multiple sclerosis. Recently Bayer HealthCare has extended the commercial production agreement for Betaferon with Boehringer Ingelheim, which received the FDA approval for Betafe
Read morePfenex, an industry leader in protein expression through the Pfenex Expression Technology™ platform, and Boehringer Ingelheim International, a leading pharmaceutical company and global leader in biopharmaceutical contract development and manufacture, announced today that th
Read moreBoehringer Ingelheim, a global leader in biopharmaceutical contract development and manufacture, and VTU Technology, a leading supplier of exclusive technologies and comprehensive services for the development of high-performance Pichia pastoris protein expression strains, announced today that the
Read moreRegional Offices
Binger Strasse 173
55216 Ingelheim am Rhein
Other
Germany
